Chemoprevention of gastric cancer by H. pylori eradication or taking aspirin: analysis of molecular alterations

Chemoprevention of gastric cancer by H. pylori eradication or taking aspirin: analysis of molecular alterations - H. pylori eradication or taking aspirin and chemoprevention of gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021857

Enrollment

100

Registered

2016-04-10

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early gastric cancer/gastric adenoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients who underwent endoscopic resection of early gastric cancer or adenoma after 3 years or more of H. pylori treatment or taking a daily aspirin. (2) Chronic gastritis patients after 3 years or more of H. pylori treatment or taking a daily aspirin. (3) H. pylori associated chronic gastritis patients.

Exclusion criteria

Exclusion criteria: (1)Patients with malignancy in other organs. (2)Patients with having a past history of esophagectomy or gastrectomy. (3)Patients who have determined by the physicians to have any reasons of unqualified.

Design outcomes

Primary

Measure	Time frame
To compare of molecular alterations related to carcinogenesis in IM or GA among H. pylori infected gastritis patients and patients with and without cancer after 3 years or more of H. pylori treatment or taking a daily aspirin.	—

Countries

Japan

Contacts

Public ContactJiro Watari

Hyogo College of Medicine Division of Gasstroenterology, Department of Internal Medicine

watarij@hyo-med.ac.jp0798-45-6662

Outcome results